Cargando…

ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca(2+)‐signalling dysregulation or toxicity in pancreatic acinar cells

BACKGROUND AND PURPOSE: Many cancer cells depend on anti‐apoptotic B‐cell lymphoma 2 (Bcl‐2) proteins for their survival. Bcl‐2 antagonism through Bcl‐2 homology 3 (BH3) mimetics has emerged as a novel anti‐cancer therapy. ABT‐199 (Venetoclax), a recently developed BH3 mimetic that selectively inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jakubowska, Monika A, Kerkhofs, Martijn, Martines, Claudio, Efremov, Dimitar G, Gerasimenko, Julia V, Gerasimenko, Oleg V, Petersen, Ole H, Bultynck, Geert, Vervliet, Tim, Ferdek, Pawel E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Themed Section: Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887725/ https://www.ncbi.nlm.nih.gov/pubmed/30266036 http://dx.doi.org/10.1111/bph.14505

Ejemplares similares

BH4 domain peptides derived from Bcl-2/Bcl-XL as novel tools against acute pancreatitis
por: Vervliet, Tim, et al.
Publicado: (2018)

BH3 mimetic-elicited Ca(2+) signals in pancreatic acinar cells are dependent on Bax and can be reduced by Ca(2+)-like peptides
por: Ferdek, Pawel E, et al.
Publicado: (2017)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

On BH3 Mimetics and Ca(2+) Signaling
por: Ferdek, Pawel E., et al.
Publicado: (2017)

Inhibitors of Bcl-2 protein family deplete ER Ca(2+) stores in pancreatic acinar cells
por: Gerasimenko, Julia, et al.
Publicado: (2010)

MiRNA-16-1 Suppresses Mcl-1 and Bcl-2 and Sensitizes Chronic Lymphocytic Leukemia Cells to BH3 Mimetic ABT-199
por: Ashofteh, Nooshin, et al.
Publicado: (2022)

Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199
por: García, Carolina Paola, et al.
Publicado: (2016)

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax
por: Ackler, Scott, et al.
Publicado: (2015)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

A Novel Role for Bcl-2 in Regulation of Cellular Calcium Extrusion
por: Ferdek, Pawel E., et al.
Publicado: (2012)

Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells
por: Bodo, Juraj, et al.
Publicado: (2016)

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
por: Kerkhofs, Martijn, et al.
Publicado: (2020)

Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
por: Pallis, Monica, et al.
Publicado: (2016)

Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions
por: Weiss, Johanna, et al.
Publicado: (2016)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
por: Baev, Denis V., et al.
Publicado: (2014)

Nitric oxide signals are interlinked with calcium signals in normal pancreatic stellate cells upon oxidative stress and inflammation
por: Jakubowska, Monika A., et al.
Publicado: (2016)

Bile acids induce necrosis in pancreatic stellate cells dependent on calcium entry and sodium‐driven bile uptake
por: Ferdek, Pawel E., et al.
Publicado: (2016)

Calcium signalling in the acinar environment of the exocrine pancreas: physiology and pathophysiology
por: Gryshchenko, Oleksiy, et al.
Publicado: (2018)

High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
por: Bate-Eya, Laurel T., et al.
Publicado: (2016)

The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma
por: Lieber, Justus, et al.
Publicado: (2011)

ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells
por: Valdez, Benigno C., et al.
Publicado: (2022)

The Growing Role of the BH3 Mimetic Drug Venetoclax in the Therapy of Acute Myeloid Leukemia
por: Pelosi, Elvira, et al.
Publicado: (2022)

Bcl-2(high) mantle cell lymphoma cells are sensitized to acadesine with ABT-199
por: Montraveta, Arnau, et al.
Publicado: (2015)

Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37
por: Green, Maja M., et al.
Publicado: (2016)

Antagonizing Bcl-2′s BH4 domain in cancer
por: Vervloessem, Tamara, et al.
Publicado: (2015)

Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies
por: Roberts, AW, et al.
Publicado: (2016)

Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine
por: Stamelos, Vasileios A, et al.
Publicado: (2012)

BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
por: Zhan, Yihong, et al.
Publicado: (2019)

Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER(+) breast cancer
por: Deng, Jing, et al.
Publicado: (2013)

The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells
por: Broecker-Preuss, Martina, et al.
Publicado: (2016)

Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner()()
por: Kiprianova, Irina, et al.
Publicado: (2015)

Selective regulation of IP(3)-receptor-mediated Ca(2+) signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl
por: Monaco, G, et al.
Publicado: (2012)

BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models
por: Vervloessem, Tamara, et al.
Publicado: (2020)

Ryanodine receptors are targeted by anti-apoptotic Bcl-X(L) involving its BH4 domain and Lys87 from its BH3 domain
por: Vervliet, Tim, et al.
Publicado: (2015)

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
por: Li, Zhaodong, et al.
Publicado: (2018)

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
por: Florent, Romane, et al.
Publicado: (2020)

Targeting MCL-1/BCL-X(L) Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
por: Lin, Kevin H., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dvct7os87dkamb5rpq3v4p7lb5